South America Pharmaceutical Glass Packaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The South America pharmaceutical glass packaging market size was valued at USD 1.47 billion in 2025 and estimated to expand from USD 1.56 billion in 2026 to reach USD 2.11 billion by 2031, at a CAGR of 6.23% during the forecast period (2026-2031). This report is segmented by Product (Bottles, Vials, Ampoules, and Prefillable Syringes, and More), by Glass Type (Type I Borosilicate, and More), by Drug Formulation (Injectables, and More), by End-User (Pharma Innovator Companies, Generic and CMOs, Biotech Firms, Compounding Pharmacies, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

South America Pharmaceutical Glass Packaging Market Trends and Insights

Expansion of Injectable and Biologic Drug Manufacturing

Brazil’s injectable manufacturing base is moving toward more complex biologics and higher-value parenteral medicines. In January 2026, Blau Farmacêutica announced fully integrated domestic development of a pembrolizumab monoclonal antibody biosimilar and reported ANVISA GMP certification for its API facility. This development supports demand for Type I borosilicate vials and prefillable syringes because biologic products require qualified primary containers. Aurobindo Pharma’s CuraTeQ Biologics received ANVISA GMP certification in July 2026 for its Hyderabad facility, including vial filling and prefillable syringe lines for biosimilar products.Each new biologic program requires container qualification before commercial supply, creating a recurring workstream for packaging suppliers. These qualification requirements also slow the replacement of glass in applications where established container performance remains important. They also tie packaging decisions to clinical and commercial timelines, since a supplier change may require further compatibility work. This gives qualified container suppliers a more durable role in biologic production programs than in lower-specification packaging categories.

Brazil Biosimilar Localization and Public Procurement

Brazil’s public procurement system supports local production through Partnerships for Productive Development, which link technology transfer to expected purchase volumes. This structure can reduce the investment risk for domestic manufacturing and create a steadier requirement for qualified glass containers. In September 2025, ANVISA issued favorable marketing authorization recommendations for biosimilars, including denosumab, trastuzumab, and aflibercept. The Funed, Samsung Bioepis, and Bionovis program for aflibercept included BRL 42 million (USD 7.4 million) in upgrades at Fundação Ezequiel Dias, based on the stated 2025 average exchange rate. Public hospitals often use multi-dose formats to reduce per-dose costs, which favors glass vial consumption. Procurement visibility, therefore, supports demand planning for suppliers capable of meeting the required quality documentation. It also shifts attention from simple unit pricing to service reliability, documentation readiness, and stable availability across tender cycles. Suppliers that can support both local manufacturing and public procurement requirements are positioned to address this demand.

Imported Raw Materials and Currency Exposure

The South America pharmaceutical glass packaging market relies on imported high-purity borosilicate tubing. This reliance leaves buyers exposed to currency movements and higher landed costs in Brazil and Argentina. Domestic production does not currently provide pharmaceutical-grade borosilicate tubing at commercial scale. Developing a furnace and tube-drawing operation requires significant capital, specialized process control, and sustained demand. Regulatory changes can also raise documentation costs when they require additional extractables and leachables evidence. Smaller generic manufacturers and compounding pharmacies may find it hardest to manage both foreign-currency exposure and specification-related costs. Procurement delays can result when buyers wait for more favorable exchange conditions or switch to lower-specification options. The issue is most immediate where contracts are priced in foreign currency and local reimbursement conditions do not change at the same pace.

Other drivers and restraints analyzed in the detailed report include:

• Growth of Ready-to-Use Sterile Packaging Platforms
• Vaccine and Fill-Finish Capacity Expansion
• Polymer Substitution in Standard Injectable Applications

Segment Analysis

Vials held 19.82% of the South America pharmaceutical glass packaging market share in 2025, supported by their broad use in vaccines, injectable biologics, and standard parenteral medicines. Their established role reflects the requirements of public and private formularies across the region. Multi-dose Type I borosilicate vials are relevant to public health programs because they support economical dosing formats. Generic manufacturers and contract manufacturing organizations also rely on familiar vial configurations with established quality records. Ampoules continued to serve injectable analgesics, anti-inflammatory medicines, and lower-value parenteral products. Bottles remained relevant to oral liquids and topical medicines, although these applications carry less glass intensity than injectables.

Cartridges and prefillable syringes are projected to expand at a CAGR of 7.49% through 2031, making them the fastest-growing product format in the South America pharmaceutical glass packaging market. Auto-injector adoption and GLP-1 receptor agonist pipelines support the shift toward patient-ready delivery formats. Biologic developers also value closed containers that can limit handling during filling operations. The Alliance for RTU was designed to help manufacturers and contract manufacturers shift toward ready-to-use vial and cartridge systems. Brazil’s use of imported components and domestic sterile assembly may enable faster adoption of these formats than a model requiring new domestic glass-forming assets. ABNT NBR 11280 for ampoules and ABNT NBR 11819 for pharmaceutical bottles remain baseline standards for suppliers serving these uses.

Type I borosilicate accounted for 27.46% of the South America pharmaceutical glass packaging market size in 2025. Its position reflects its use in biologics, vaccines, and sensitive injectable products. The material offers the hydrolytic resistance expected for high-value parenteral medicines. Suppliers benefit when customers prefer an established material rather than undertake a new container qualification process. Type II treated soda-lime glass serves aqueous injectables with controlled interaction risk. Type III soda-lime glass remains suitable for oral liquid bottles and selected veterinary uses where high hydrolytic resistance is less critical.

Type I borosilicate is projected to expand at a CAGR of 7.23% through 2031, the highest rate among glass categories in the South America pharmaceutical glass packaging market. Biosimilars, monoclonal antibodies, and GLP-1 medicines are supporting demand for high-specification primary containers. Regulatory documentation requirements can reinforce this preference because Type I glass carries a recognized performance history in parenteral applications. The share gap between Type I and treated or standard soda-lime grades can therefore widen as complex injectables take a larger role in public procurement. The product mix also raises the value placed on low-defect tubing, robust quality records, and regional technical support. This favors suppliers that can pair glass supply with qualification assistance.

Complete Report Scope:

• By Product
  • Bottles
  • Vials
  • Ampoules
  • Cartridges and Prefillable Syringes
  • Other Products
• By Glass Type
  • Type I Borosilicate
  • Type II Treated Soda-Lime
  • Type III Soda-Lime
  • Other Glass Types
• By Drug Formulation
  • Injectables
  • Oral Liquids
  • Ophthalmic/Nasal
  • Topical
• By End-User
  • Pharma Innovator Companies
  • Generic and CMOs
  • Biotech Firms
  • Compounding Pharmacies
  • Veterinary Pharma
• By Geography
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America

List of Companies Covered in this Report:

• Gerresheimer AG
• SCHOTT AG
• Stevanato Group S.p.A.
• Nipro Corporation
• SGD S.A.
• Corning Incorporated
• West Pharmaceutical Services, Inc.
• Bormioli Pharma S.p.A.
• Ardagh Glass Packaging
• Stoelzle Oberglas GmbH
• Beatson Clark Limited
• Shandong Pharmaceutical Glass Co., Ltd.
• Chongqing Zhengchuan Pharmaceutical Packaging Co., Ltd.
• Cangzhou Four Star Glass Co., Ltd.
• DWK Life Sciences GmbH
• Origin Pharma Packaging Limited
• Vitro, S.A.B. de C.V.
• AptarGroup, Inc.
• Becton, Dickinson and Company
• Owens-Illinois, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support